TMEM37 and chronic myelogenous leukemia, BCR-ABL1 positive: Although the data from this study shows that functional immunity to PR1 persists during unmaintained remission of CML, it does not demonstrate that PR1-CTL immunity is the sole driver of sustained molecular remission.